SCHEMBL2240447

SCHEMBL2240447

CNc1cc(-c2cncc(-c3cccc(OC)c3)c2)nc(-c2cccc(C)n2)n1

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADORA1 P30542 3/20 0.45
ADORA2A P29274 2/20 0.45
ADORA3 P0DMS8 2/20 0.45
ADORA2B P29275 2/20 0.45
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
CYP3A4 P08684 4/20 0.40
TGFBR2 P37173 1/20 0.40
ABCG2 Q9UNQ0 2/20 0.40
TP53 P04637 2/20 0.40
MAPT P10636 2/20 0.40
ABCB1 P08183 1/20 0.40
ABCC1 P33527 1/20 0.40
KDR P35968 1/20 0.40
TGFBR1 P36897 1/20 0.40
CYP1A2 P05177 3/20 0.40
CYP2C9 P11712 2/20 0.40
CLK4 Q9HAZ1 1/20 0.39
GRM5 P41594 1/20 0.39
CYP2A6 P11509 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2245647 0.90 CYP11B1 (0.43) ADORA1ADORA2AADORA3ADORA2BCYP11B1
SCHEMBL2238727 0.86 NPC1 (0.52) ADORA1ADORA2AADORA3ADORA2BCYP11B1
SCHEMBL2240368 0.85 ADORA2A (0.47) ADORA1ADORA2ATGFBR1CLK4
SCHEMBL2240439 0.83 CYP11B1 (0.43) CYP11B1CYP11B2CYP3A4TP53MAPT
SCHEMBL2240583 0.82 CYP1A2 (0.46) CYP3A4TP53MAPTCYP1A2CYP2C9
SCHEMBL2244967 0.82 CYP1A2 (0.44) ADORA1ADORA2AADORA3ADORA2BCYP11B1
SCHEMBL2244227 0.81 TGFBR1 (0.42) ADORA1ADORA2AADORA3TGFBR2TGFBR1
SCHEMBL2239529 0.81 BPTF (0.43) CYP11B2CYP3A4TGFBR1CYP1A2CYP2A6
SCHEMBL2240550 0.80 CDK8 (0.41) CYP11B2TGFBR1CYP2A6
SCHEMBL2239526 0.79 IRAK4 (0.45) ADORA1ADORA2ATGFBR1CYP2A6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP claimed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US claimed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP claimed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO claimed
EP-2044056-B1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2012-08-22 EP disclosed
US-7989458-B2 Pyrimidine derivatives as alk-5 inhibitors NOVARTIS AG (CH) 2011-08-02 US disclosed
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors NOVARTIS AG (CH) 2009-08-20 US disclosed
EP-2044056-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS Novartis Ag (CH) 2009-04-08 EP disclosed
WO-2008006583-A1 PYRIMIDINE DERIVATIVES AS ALK-5 INHIBITORS NOVARTIS AG (CH) 2008-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090209539-A1 Pyrimidine derivatives as alk-5 Inhibitors ALK, ACVR1, MUSK ADORA1 432/4885ADORA2A 1450/4885ADORA3 754/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.